About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 1463 record(s)
Req # A-2022-000177
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-102130-986.Organization: Health Canada
December 2022
Req # A-2022-000221
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-115561-42.Organization: Health Canada
December 2022
Req # A-2022-000548
Adverse Drug Reactions (ADRs) for MESALAZINE. Report numbers: 000990672, E2B_05361971, E2B_05323624, E2B_05368162, 000992474. ADRs for VYVANSE. Report numbers: E2B_05347288, 000992979. ADRs for C1 ESTERASE INHIBITOR (HUMAN). Report numbers: E2B_05309974, E2B_05344993, E2B_05349867.Organization: Health Canada
December 2022
Req # A-2022-000564
Adverse Drug Reactions (ADRs). Report numbers: E2B_03869816, E2B_05154894, 000975026, E2B_03352321, E2B_04836615, E2B_04910255, E2B_04938543, 000975659, E2B_04921222, E2B_04926643.Organization: Health Canada
December 2022
Req # A-2022-000683
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-105570-697.Organization: Health Canada
December 2022
Req # A-2022-000698
Adverse Drug Reactions (ADRs). Report numbers: E2B_04321809, E2B_02770462, E2B_05372962, E2B_05415740, E2B_05400872, E2B_05104991, E2B_05332603, E2B_05363858, E2B_05414160, E2B_05415560.Organization: Health Canada
December 2022
Req # A-2022-000719
Adverse Drug Reactions (ADRs) for OLMETEC. Report numbers: E2B_01486139, E2B_01422947, 000705509. ADR for PRINIVIL. Report number: E2B_01399419. ADRs for PROMETRIUM. Report numbers: E2B_00758389, E2B_01735915, E2B_01740582, E2B_00451784, E2B_00758389. ADR for PROPECIA. Report number: 000700926.Organization: Health Canada
December 2022
Req # A-2022-000789
Adverse Drug Reaction (ADR) for PROSCAR. Report number: 000697897. ADRs for REMERON. Report numbers: E2B_01107793, E2B_01502801.Organization: Health Canada
December 2022
Req # A-2022-000801
Adverse Drug Reactions (ADRs). Report numbers: E2B_05472711, 000994886, E2B_05518379, 000984000, E2B_05432033, 000995186, 000982655, E2B_05424693, E2B_05470576, 000998615.Organization: Health Canada
December 2022
Req # A-2022-000809
Adverse Drug Reaction (ADR). Report number: E2B_05593974.Organization: Health Canada
December 2022